Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [14840]

ASCO 2024: Experimental therapy shows promise in pancreatic cancer clinical trial

ASCO 2024: Experimental therapy shows promise in pancreatic cancer clinical trial

ASCO 2024: Drug targeting protein involved in control of immune response produces encouraging results in glioblastoma

ASCO 2024: Drug targeting protein involved in control of immune response produces encouraging results in...

ASCO 2024: CAR T-cell therapy shows promise in patients with central nervous system lymphoma

ASCO 2024: CAR T-cell therapy shows promise in patients with central nervous system lymphoma

ASCO 2024: Antibody-drug conjugate plus checkpoint inhibitor shows a trend toward improved progression-free survival in PD-L1-positive hormone receptor-positive, HER2-negative breast cancer

ASCO 2024: Antibody-drug conjugate plus checkpoint inhibitor shows a trend toward improved progression-free...

ASCO 2024: Trastuzumab deruxtecan significantly improves progression-free survival In breast cancer patients previously treated with endocrine therapy

ASCO 2024: Trastuzumab deruxtecan significantly improves progression-free survival In breast cancer patients...

ASCO 2024: Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer

ASCO 2024: Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal...

ASCO 2024: Durvalumab following chemoradiotherapy improved survival in patients with limited-stage small-cell lung cancer

ASCO 2024: Durvalumab following chemoradiotherapy improved survival in patients with limited-stage small-cell lung...

ASCO 2024: Osimertinib poised to change standard of care treatment for patients with locally advanced EGFR-mutated NSCLC

ASCO 2024: Osimertinib poised to change standard of care treatment for patients with locally advanced EGFR-mutated...

ASCO 2024: Dual immunotherapy treatment before surgery, rather than after, improves outcomes in melanoma patients

ASCO 2024: Dual immunotherapy treatment before surgery, rather than after, improves outcomes in melanoma patients

ASCO 2024: Lymphadenectomy may not be needed for patients with advanced ovarian cancer

ASCO 2024: Lymphadenectomy may not be needed for patients with advanced ovarian cancer

More from ecancer